Video: Arsanis’ MAb Cocktail Takes Aim at Deadly S. Aureus

Aureus

A relatively young company, Austro-American biopharma Arsanis Biosciences Inc. is taking on a big problem: severe, hospital-acquired Staphylococcus aureus infections. President and CEO Eszter Nagy updated BioWorld on the status of its weapon of choice, a MAb cocktail: ASN-100. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

For Ebola Victory, Scientific Advances Could Help with Nonscientific Challenges

ebola

From a purely scientific standpoint, the news about the Ebola outbreak has been encouraging. New genomic technologies enable unprecedented surveillance of the virus. There are drugs and vaccines in clinical trials. And in response to the urgency of the crisis, both drugmakers and regulatory agencies are making efforts to expedite the process of getting weapons against Ebola through the regulatory process and into the field, where they are needed. (See BioWorld Today, Oct. 22, 2014.) (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Analysts Cheer Amgen Earnings, Biosimilars

amgen

Amgen Inc.’s moves into the biosimilar space drew attention during the company’s business review meeting, which followed the release of investor-pleasing third quarter financial results that showed the company beating estimates and included higher guidance for the full year’s earnings.

Piper Jaffray analyst Joshua Schimmer called Thousand Oaks, Calif.-based Amgen “hands down, the best large cap pipeline around. While no new data were presented, the company highlighted its late-stage product portfolio which we believe is unrivaled in its incremental revenue-generating potential.” (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Shining the Spotlight on Immuno-Oncology Combinations

immuno-oncology

Compared with the relatively non-specific cytotoxic drugs currently used in most cancer treatments, a new era of cancer therapy is expected to be dominated by targeted treatments and cancer immunotherapies. Targeted and immunotherapies targeting specific pathways or receptors provide an advantage over traditional chemotherapies that act on all rapidly dividing cells, be they normal or cancerous. The side effects of chemotherapy are much greater due to their effects on normal cells, whereas targeted therapies cause little or no collateral damage to normal cells, which improves the quality of life of the cancer patient. The use of targeted therapy has also markedly changed the outcomes for some cancers. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Cleveland Clinic Medical Innovation Summit Offers Glimpse into Healthcare’s Future

Cleveland Clinic

Personalized medicine. Big data. Wellness. The growing impact of diagnostics on pharmaceuticals. The med-tech buzzwords and ideas of yesterday are actually the innovations of today. Those once abstract ideas were more tangible and were present during this year’s Cleveland Clinic Medical Innovation Summit, which was held last month. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Video: A Candid Update from Sciclone’s CEO on FCPA Investigation

FCPA

Friedhelm Blobel, CEO, Sciclone Pharmaceutical Inc. spoke with BioWorld about the ongoing investigation related to possible violations of the U.S. Foreign Corrupt Practices Act (FCPA) in China. He also discussed the company’s resulting compliance program and confirmed that, despite these challenges, being in China outweighs all of the expenses and risks. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Health Experts: Say No to Randomized Trials Testing Ebola Drugs

ebola

Leading health experts said that having decided it is ethical to use non-approved products to help deal with the Ebola virus epidemic, it would be unethical if those drugs were administered in the context of randomized clinical trials. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Humira is in the Crosshairs as Amgen gets its First Phase III Biosimilars Win

Humira

Amgen Inc. put the biopharma world on notice by disclosing positive findings from the first phase III study evaluating efficacy and safety of its lead biosimilar candidate. The randomized, double-blind, active-controlled study of ABP 501, whose reference drug is Humira (adalimumab, Abbvie Inc.), met its primary endpoint: improving the Psoriasis Area and Severity Index (PASI) within a prespecified equivalence margin, compared to adalimumab, from baseline to week 16 in patients with moderate to severe plaque psoriasis. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Life Sciences Merger and Acquisitions in Q3 2014

Albemarle

The M&A activity in the Life Sciences sector in Q3 2014, as expected, experienced a slowdown for tax inversion deals, looking at the regulatory uncertainty and scrutiny from the US agencies.

The quarter-over-quarter total disclosed deal value dropped by 45% from $90 billion in Q2 to $50 billion in Q3, as per Thomson Reuters Recap. However, the sector registered highest deal activity with 112 deals in Q3 as compared to 88 and 93 deals in Q1 and Q2, respectively. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Bladder Cancer: New Drugs in the Pipeline & the Role of Biomarkers

bladder cancer

Bladder cancer is one of the ten most prevalent solid tumors worldwide, particularly in Westernized countries. With a median age of diagnosis of 73 years and a 4:1 predominance of male patients, the malignancy is closely linked to risk factors such as tobacco smoking, the effects of which may be amplified in the presence of genetic risk factors. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone